Understanding how type I interferons affect the formation of inhibitors in hemophilia A patients
The Role of Type I Interferons in Factor VIII Inhibitor Formation
This study is looking at how certain immune signals might cause some people with severe hemophilia A to develop inhibitors against a treatment factor, which can make managing bleeding harder; it aims to find ways to predict and prevent this from happening in patients who are at risk.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Emory University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project ID | NIH-10906955 on NIH RePORTER |
What this research studies
This research investigates the role of type I interferons in the formation of anti-factor VIII (FVIII) alloantibodies, known as inhibitors, in patients with severe hemophilia A. The study aims to identify the mechanisms that lead to inhibitor development, which complicates bleeding management and reduces quality of life. By exploring the pathways that initiate this process, the research seeks to find potential predictive markers and preventive strategies for at-risk patients. The approach includes examining the effects of specific immune cells and genetic factors on inhibitor formation.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with severe hemophilia A who are at risk of developing inhibitors following FVIII therapy.
Not a fit: Patients with mild hemophilia or those who have not received FVIII therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new strategies for predicting and preventing inhibitor formation in hemophilia A patients, improving their treatment outcomes.
How similar studies have performed: Previous research has shown promising results in understanding immune responses related to alloantibody formation, suggesting that this approach may yield significant insights.
Where this research is happening
Atlanta, United States
- Emory University — Atlanta, United States (Active)
Researchers
- Principal investigator: Zerra, Patricia Elizabeth — Emory University
- Study coordinator: Zerra, Patricia Elizabeth
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.